These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31391099)

  • 1. Benzbromarone in the treatment of gout.
    Azevedo VF; Kos IA; Vargas-Santos AB; da Rocha Castelar Pinheiro G; Dos Santos Paiva E
    Adv Rheumatol; 2019 Aug; 59(1):37. PubMed ID: 31391099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
    Lee MH; Graham GG; Williams KM; Day RO
    Drug Saf; 2008; 31(8):643-65. PubMed ID: 18636784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
    Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
    J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity.
    Wang H; Peng Y; Zhang T; Lan Q; Zhao H; Wang W; Zhao Y; Wang X; Pang J; Wang S; Zheng J
    Drug Metab Dispos; 2017 Dec; 45(12):1354-1363. PubMed ID: 29021351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Uricosuric agent].
    Ohno I
    Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
    Tan PK; Liu S; Gunic E; Miner JN
    Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
    Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
    Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation.
    Ohe T; Umezawa R; Kitagawara Y; Yasuda D; Takahashi K; Nakamura S; Abe A; Sekine S; Ito K; Okunushi K; Morio H; Furihata T; Anzai N; Mashino T
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3708-3711. PubMed ID: 30389287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
    Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
    J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
    Jansen TL; Perez-Ruiz F; Tausche AK; Richette P
    Clin Rheumatol; 2018 Dec; 37(12):3159-3165. PubMed ID: 30244431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?
    Gravatt L
    N Z Med J; 2013 Sep; 126(1382):118-9. PubMed ID: 24154779
    [No Abstract]   [Full Text] [Related]  

  • 15. Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone.
    Huang W; Jiao S; Chen S; Chen Y; Yang Z; Wang W; Cao Z; Li Z; Zhang L
    Bioorg Med Chem; 2022 Dec; 75():117073. PubMed ID: 36347120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?
    Jansen TL; Reinders MK; van Roon EN; Brouwers JR
    Clin Exp Rheumatol; 2004; 22(5):651. PubMed ID: 15485024
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study.
    Kang EH; Shin A; Park CS; Lee EB; Lee YJ; Curhan G; Choi HK
    Rheumatology (Oxford); 2024 Sep; 63(9):2433-2441. PubMed ID: 38733596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
    Zhao T; Meng Q; Sun Z; Chen Y; Ai W; Zhao Z; Kang D; Dong Y; Liang R; Wu T; Pang J; Liu X; Zhan P
    J Med Chem; 2020 Oct; 63(19):10829-10854. PubMed ID: 32897699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA.
    Nindita Y; Hamada T; Bahrudin U; Hosoyamada M; Ichida K; Iwai C; Urashima S; Kuwabara M; Utami SB; Mizuta E; Yamada K; Igawa O; Shigemasa C; Ninomiya H; Tsuchihashi T; Hisatome I
    Arzneimittelforschung; 2010; 60(4):186-8. PubMed ID: 20486468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.